Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 07/27 09:15:27 pm
76.493 EUR   -0.10%
01:30pDJSANOFI : 2Q 2016 -- Forecast
07/26 SANOFI : India ends in green; SC refuses early hearing
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:30pDJSANOFI : 2Q 2016 -- Forecast
07/26 SANOFI : India ends in green; SC refuses early hearing
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
07/26SANOFI SA : half-yearly earnings release
07/26 SANOFI PASTEUR : Ships First of its 2016-2017 Seasonal Influenza Vaccine Doses i..
07/25 SANOFI : India zooms 2.7% after strong Q1 nos
07/23 SANOFI INDIA : Q2 NET UP 33% AT Rs85 CRORE
07/22 PROMIS NEUROSCIENCES : Announces Appointment of Dr. Johanne Kaplan as Chief Deve..
07/21 SANOFI : Information concerning the total number of voting rights and shares, pr..
07/21 JUNIPER PHARMACEUTICALS : Appoints Alicia Secor President and Chief Executive Of..
More news
Sector news : Pharmaceuticals - NEC
08:59p Teva purchase of Allergan generics business gets OK with conditions
08:08pDJBAYER : Reports Higher Second-Quarter Profit, Raises Guidance -- 3rd Update
07:11pDJPFIZER : Cleared to Buy Nanotech Drug Firm Bind Therapeutics
07:02pDJVECTURA : Initiates Legal Proceedings Against GSK
05:01pDJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:10p MANNKIND : Beware Of Dog
08:18a MY EARNINGS GAME PLAN : July 28-29
07/25 Is Biotech Finally Ready To Move Higher?
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 MannKind - Afrezza Sales Pacing Below My Bearish Line - Reality May Sting
Advertisement
Financials (€)
Sales 2016 37 154 M
EBIT 2016 9 361 M
Net income 2016 5 093 M
Debt 2016 5 594 M
Yield 2016 3,92%
P/E ratio 2016 17,76
P/E ratio 2017 16,14
EV / Sales 2016 2,81x
EV / Sales 2017 2,76x
Capitalization 98 692 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,0 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.58%108 516
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results